Market Snapshot

Market Synopsis:

Global Automated Breast Ultrasound System (ABUS) market is valued at USD 705.5 Million in 2021 and is projected to attain a value of USD 1807.3 Million by 2028 at a CAGR of 15.9% during the forecast period, 2022–2028. Patients may experience discomfort as a result of chemotherapy equipment. The needle or guide wire can damage the top of the lung during the insertion of a skin-tunneled catheter or port, generating an air pocket. There may be bruising at the location where the needle entered the vein, or an artery or nerve may be damaged. Furthermore, infection is a possibility. The risk is usually one to three in every 100 instances, although it might be higher based on a variety of other circumstances, such as diagnosis or therapy. There's also the possibility of a clot forming around the port. The CVAD can split, become damaged, or become dislocated if it is not in the proper position, so it must be replaced.

Ultrasound examines organs and structures inside the body using high-frequency sound waves. There is no radiation involved with this method. A transducer that scans the entire breast is used in automated breast ultrasonography to obtain three-dimensional (3D) ultrasound pictures for cancer diagnosis.

Technology Advancement

One of the primary factors boosting the worldwide automated breast ultrasound system market is technological advances in breast cancer detection equipment. Several additional technologies are being developed by companies to improve cancer screening in people with thick breasts, enhancing the efficiency of breast cancer detection. ABUS innovations are also expected to solve flaws in traditional systems. Customer acceptance of improved cancer imaging will increase as a result of such technological advancements, boosting industry growth.

Stringent Regulations

The use of automated breast ultrasound imaging techniques has been restricted in a number of countries due to rigorous laws. Furthermore, the high cost of ultrasound systems in comparison to traditional cancer screening methods is likely to stifle the global automated breast ultrasound system (ABUS) market's growth. For example, a new ABUS can cost around $300,000 on average. Although ultrasonography is speedy and effective in detecting cancer, it is also prone to false-positive biopsies, which is predicted to limit market growth.

The Automated Breast Ultrasound System (ABUS) market scope can be tabulated as below:

Market Segmentation:

The Global Automated Breast Ultrasound System (ABUS) Market can be segmented by Product into Automated Breast, Ultrasound System, Automated Breast Volume Scanner and Others. Based on Application into Hospitals, Diagnostics Imaging Laboratories, Clinics and Others. Based on Region, the Automated Breast Ultrasound System (ABUS) Market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

North America to Continue Dominating the Automated Breast Ultrasound System (ABUS) Market

Because of the rising incidence of cancer and the presence of key competitors in the region, North America accounted for the greatest revenue share in 2021. Furthermore, even women without a history of cancer are advised to begin mammograms when they reach the age of 40 or 50, according to US screening standards. They are also advised to continue once every one or two years, and this is done on a regular basis until the age of 75. This is a crucial aspect that is predicted to promote market expansion in the region in the future. Based on these figures and projections, the market in the region is likely to grow at a high rate in the future.

Key Players:

Key participants operating in the Automated Breast Ultrasound System (ABUS) market are: GE Healthcare (US), Siemens AG (Germany), Koninklijke Philips N.V. (Netherlands), Hitachi Ltd. (Japan), and SonoCine Inc. (US).

The Automated Breast Ultrasound System (ABUS) market is segmented as follows:

• Product
  • Automated Breast Ultrasound System
  • Automated Breast Volume Scanner
  • Others